Advanced Enzyme Technologies Q2 FY27 Share Price & Earnings Call Analysis

Part of: Nifty Microcap 250 · Nifty Total Market

₹284.20-1.41% today
Market cap
₹3,115 Cr
P/E
19.16
ROE
10.52%
PEG
1.39
Price to sales
3.99
Debt to equity
0.03
52W high / low
₹392 / ₹248
Sales growth (5Y)
8.24%
EBITDA margin
30.40%
Net profit margin
22.15%
Promoter holding
43.56%
Sales (last year)
₹782 Cr

Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]

Guidance scorecard · Q2 FY27 call

What Advanced Enzyme's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#79of 87 in
Pharmaceuticals & Biotechnology

RevenueQ2 FY27 call

10–20%
  • Company expects overall growth at a mid to lower mid double-digit rate over the longer term (FY27 and FY28).
  • Budgeting and more specific outlook expected by Feb-Mar next year.
  • Sustained strong growth anticipated across all segments including Human Healthcare, Animal Healthcare, Bio-Processing, and Specialized Manufacturing.
  • U.S. market shows signs of turnaround with expected pickup towards year-end, which could positively impact growth.
  • Growth driven by a combination of new customers, new products, and expanding geographies.
  • SciTech (Specialized Manufacturing) segment showing robust traction with broad-based customer growth.

2 more points from Advanced Enzyme's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Advanced Enzyme said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Capex guidance for FY27 remains at approximately INR123 crores, which includes R&D and maintenance capex.
  • Around INR52 crores of this capex has already been spent in H1 of FY27.
  • The company continues to invest in R&D, new product development, and sales team strengthening.
  • There is an emphasis on operational efficiencies and expanding production capacity, e.g., at SciTech with shift improvements.
Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Advanced Enzyme said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

Ask what Advanced Enzyme said on the order book →

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹18,347 Cr—
440%+Flat₹8,418 Cr32.3
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Financials of Advanced Enzyme

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Advanced Enzyme

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +43.62%43.50%43.02%42.95%42.92%43.08%43.08%43.08%43.04%43.26%43.25%43.56%
FIIs +22.54%23.01%12.03%12.63%12.57%11.90%23.45%25.41%25.85%25.50%26.70%26.64%
DIIs +6.98%7.56%8.08%8.02%8.17%8.19%8.45%6.41%5.51%5.41%4.77%1.89%
Public +26.88%25.95%36.87%36.40%36.31%36.82%25.00%25.09%25.62%25.85%25.28%27.90%
No. of Shareholders73,03468,64065,22266,75867,35165,32267,58969,63768,05166,19363,59967,468

Financials of Advanced Enzyme

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +158161158155146169167186185172203192215
YoY Sales growth+14%+13%+14%+5%-7%+5%+6%+20%+26%+2%+22%+3%+16%
Expenses +107107102103104114122129124123140139142
Operating Profit51545551425546566049635372
OPM %32%33%35%33%29%33%27%30%33%29%31%28%34%
Other Income +614-671089910207119
Interest1111111111111
Depreciation99999910101010101011
Profit before tax48594049425343556058605469
Tax %27%28%25%28%21%27%38%26%25%26%24%28%26%
Net Profit +35423035333927404543453951
EPS in Rs3.083.742.533.052.943.372.373.573.873.803.843.314.31

Financials of Advanced Enzyme

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +222293329391420444502529541624637746782
Sales growth-7%+32%+12%+19%+7%+6%+13%+5%+2%+15%+2%+17%+11%
Expenses +131155177226236241269327382418441515544
Operating Profit91138152165184203232203158206196230238
OPM %41%47%46%42%44%46%46%38%29%33%31%31%30%
Other Income +1-33156962121334647
Interest9849543334543
Depreciation991318212628353535374041
Profit before tax74118137139162179210171140188187233240
Tax %31%35%32%33%28%26%28%28%26%27%28%25%
Net Profit +51779394116133151124104137134174178
EPS in Rs4.606.978.208.079.9511.5813.0910.709.4511.9211.7215.0715.26
Dividend Payout %4%3%5%6%6%5%7%9%11%43%44%36%

Financials of Advanced Enzyme

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital22222222222222222222222222
Reserves1882564425376578179481,0661,2131,3021,3981,6101,643
Borrowings +1151015467352823353447393254
Other Liabilities +92716510291104153137142150151170187
Total Liabilities4174505837278059711,1461,2601,4111,5211,6111,8341,906
Fixed Assets +287285421491495563601619649650679692724
CWIP57811101010152241225183
Investments0000111124121102360403480584488
Other Assets +125158153226188275413524380427430507610
Total Assets4174505837278059711,1461,2601,4111,5211,6111,8341,906

Financials of Advanced Enzyme

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +5493107116129141163122140141142157
Cash from Investing Activity +-15-10-60-60-124-43-272-286-65-89-72
Cash from Financing Activity +-36-63-65-2-43-39-26-48-26-59-73-70
Net Cash Flow221-1854-386010975-17117-2015
Free Cash Flow428897105116901439510294108105
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit88%88%105%97%70%94%94%87%112%93%103%96%

Financials of Advanced Enzyme

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days615255555161636168586671
Inventory Days403358352339363361346402343375378335
Days Payable896857784643566067404776
Cash Conversion Cycle374342351315369379353404344393397331
Working Capital Days-4337647729094116109102112116
ROCE %25%36%31%25%24%22%22%16%12%15%13%14%

Guidance history

How Advanced Enzyme's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →10–20%FlatPlanned——
Q1 FY27 call →10–20%FlatPlanned—Rising
Q4 FY26 call →10–20%FlatPlanned—Rising
Q3 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

15out of 100

Momentum score · price trend

15 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,920 stocks
Last 12 months−9.9%44%
Last 6 months−21.5%18%
Last 3 months−13.6%29%

The price is 47.9% below its all-time high of ₹538.05 (20 Sept 2024). Stocks more than 20% below their peak have their score halved, so 30 became 15.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,920 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Advanced Enzyme: 0.4 × 44 + 0.4 × 18 + 0.2 × 29 = 30, halved to 15 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 6 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Others in Pharmaceuticals & Biotechnology this season

  • Divis Laboratories (Q2 FY27)

    Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec

  • Infinium Pharma (Q2 FY27)

    3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto

  • Walpar Nutrition (Q2 FY27)

    3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp

  • Kilitch Drugs (Q2 FY27)

    14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.